Nanobiotix resumes its negotiations on Euronext Paris

On May 21, 2026, Nanobiotix announced the resumption of trading in its ordinary shares on Euronext Paris. The biotechnology company, specializing in innovative therapeutic approaches for cancer treatment, had suspended trading earlier that day to finalize a global offering.

This suspension followed an offering comprised of ADSs in the United States and shares intended for qualified investors in Europe. This is a two-stage fundraising strategy that includes prefunded warrants to maximize the company's attractiveness to a broad range of international investors.

Trading resumed at 3:30 p.m. Paris time, allowing investors to adjust their positions in light of the new terms of this global offering. Nanobiotix hopes this will strengthen its market presence and support its advanced clinical research.